½ÃÀ庸°í¼­
»óǰÄÚµå
1672078

¼¼°èÀÇ Á¤¸ÆÇ÷Àü»öÀüÁõ Ä¡·á ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2025-2033³â)

Global Venous Thromboembolism Treatment Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 194 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Á¤¸ÆÇ÷Àü»öÀüÁõ Ä¡·á ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 18¾ï 1,000¸¸ ´Þ·¯¿¡¼­ 2033³â 27¾ï ´Þ·¯·Î 2026³âºÎÅÍ 2033³â±îÁö ¿¹Ãø ±â°£ µ¿¾È 4.53%ÀÇ °ß°íÇÑ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¤¸ÆÇ÷Àü»öÀüÁõ(VTE) Ä¡·á ½ÃÀåÀº ½ÉºÎÁ¤¸ÆÇ÷ÀüÁõ(DVT)°ú Æó»öÀüÁõ(PE)À» Æ÷ÇÔÇÑ VTE ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ÈûÀÔ¾î Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ½ÉºÎÁ¤¸ÆÇ÷ÀüÁõ(DVT)°ú Æó»öÀüÁõ(PE)À» Æ÷ÇÔÇÑ VTE ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ µû¶ó VTE °ü·Ã À§Çè¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ÀÇ·á ¼­ºñ½º Á¦°øÀÚµéÀº È¿°úÀûÀÎ ¿¹¹æ ¹× Ä¡·á Àü·«À» ¿ì¼±¼øÀ§¿¡ µÎ°í ÀÖ½À´Ï´Ù. Á÷Á¢ °æ±¸¿ë Ç×ÀÀ°íÁ¦(DOAC) ¹× ±âÁ¸ Ç×ÀÀ°íÁ¦¸¦ Æ÷ÇÔÇÑ Ç×ÀÀ°í ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖÀ¸¸ç, ÀÓ»óÀǵéÀº ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí VTE °ü·Ã ÇÕº´Áõ ¹ß»ý·üÀ» ³·Ãß±â À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù.

Ä¡·á ¿É¼Ç°ú Åõ¿© ¹æ¹ýÀÇ Çõ½ÅÀÌ VTE Ä¡·á ½ÃÀåÀÇ ¹Ì·¡¸¦ Çü¼ºÇϰí ÀÖ½À´Ï´Ù. ¾ÈÀü¼º ÇÁ·ÎÆÄÀϰú Åõ¿© ¿ä¹ýÀ» °³¼±ÇÑ »õ·Î¿î Ç×ÀÀ°íÁ¦ÀÇ °³¹ßÀº VTE °ü¸®ÀÇ Ä¡·á ȯ°æÀ» °³¼±Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿þ¾î·¯ºí ±â±â ¹× ¿ø°ÝÀÇ·á ¼Ö·ç¼Ç°ú °°Àº ȯÀÚ ¸ð´ÏÅ͸µ ±â¼úÀÇ ¹ßÀüÀ¸·Î ÀÇ·áÁøÀº ȯÀÚÀÇ ¼øÀÀµµ¿Í °á°ú¸¦ º¸´Ù È¿°úÀûÀ¸·Î ÃßÀûÇÒ ¼ö ÀÖ°Ô µÇ¾úÀ¸¸ç, VTEÀÇ ±Ùº»ÀûÀÎ ¸ÞÄ¿´ÏÁò¿¡ ´ëÇÑ ¿¬±¸°¡ ÁøÇàµÊ¿¡ µû¶ó ƯÁ¤ À§Çè ¿äÀÎ ¹× ȯÀÚ Áý´Ü¿¡ ´ëÇÑ Ç¥Àû Ä¡·áÀÇ µµÀÔÀÌ °¡´ÉÇØÁ³½À´Ï´Ù.

¶ÇÇÑ, Á¦¾àȸ»ç¿Í Çа谡 ÀÌ ºÐ¾ßÀÇ ¹ÌÃæÁ· ¼ö¿ä¸¦ ÀνÄÇÔ¿¡ µû¶ó VTE Ä¡·á ½ÃÀåÀº ÀÓ»ó ¿¬±¸ ¹× °³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡ÀÇ ÇýÅÃÀ» ´©¸± ¼ö ÀÖÀ» °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÓ»ó½ÃÇèÀ» ÁøÇàÇϰí Çõ½ÅÀûÀÎ Ä¡·á¹ýÀ» ¼º°øÀûÀ¸·Î °³¹ßÇϱâ À§Çؼ­´Â ÀÇ·á ¼­ºñ½º Á¦°øÀÚ, ¿¬±¸ÀÚ ¹× ¾÷°è ÀÌÇØ°ü°èÀÚµéÀÇ Çù·ÂÀÌ ÇʼöÀûÀÔ´Ï´Ù. ±ÔÁ¦ ȯ°æÀÌ ¹ßÀüÇÔ¿¡ µû¶ó ±ÔÁ¦ ±â°üÀº »õ·Î¿î Ä¡·á¹ýÀÇ ½ÂÀÎ ÀýÂ÷¸¦ °£¼ÒÈ­Çϰí VTE ȯÀÚ¸¦ À§ÇÑ È¿°úÀûÀÎ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ½Å¼ÓÇÑ Á¢±ÙÀ» ÃËÁøÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ¾ÕÀ¸·Î VTE °ü¸®¸¦ Á¾ÇÕÀûÀÎ ÇコÄɾî Àü·«¿¡ ÅëÇÕÇÏ´Â ¹æÇâÀ¸·Î Á¡Á¡ ´õ ¸¹Àº ÃÊÁ¡ÀÌ ¸ÂÃçÁú °ÍÀ̸ç, ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϱâ À§ÇÑ ¿¹¹æ, Á¶±â ¹ß°ß, °³º°È­µÈ Ä¡·á °èȹÀÇ Á߿伺ÀÌ °­Á¶µÉ °ÍÀÔ´Ï´Ù.

´ç»çÀÇ º¸°í¼­´Â °í°´¿¡°Ô ´Ù¾çÇÑ »ê¾÷ ¹× ½ÃÀå¿¡ ´ëÇÑ Æ÷°ýÀûÀÌ°í ½Ç¿ëÀûÀÎ ÀλçÀÌÆ®¸¦ Á¦°øÇϱâ À§ÇØ ¼¼½ÉÇÏ°Ô ÀÛ¼ºµÇ¾ú½À´Ï´Ù. °¢ º¸°í¼­´Â ½ÃÀå »óȲÀ» ¿ÏÀüÈ÷ ÀÌÇØÇϱâ À§ÇØ ¸î °¡Áö Áß¿äÇÑ ¿ä¼Ò¸¦ Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù:

½ÃÀå °³¿ä : Á¤ÀÇ, ºÐ·ù, »ê¾÷ ÇöȲ µî ½ÃÀå¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ ¼Ò°³.

½ÃÀå ÃËÁø¿äÀÎ : ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ½ÃÀå ÃËÁø¿äÀÎ ¹× °úÁ¦¸¦ »ó¼¼È÷ ºÐ¼®ÇÕ´Ï´Ù. ÀÌ ¼½¼Ç¿¡¼­´Â ±â¼ú ¹ßÀü, ±ÔÁ¦ º¯È­, »õ·Î¿î Æ®·»µå µîÀÇ ¿äÀÎÀ» °ËÅäÇÕ´Ï´Ù.

¼¼ºÐÈ­ ºÐ¼® : Á¦Ç° À¯Çü, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ª µîÀÇ ±âÁØ¿¡ µû¶ó ½ÃÀåÀ» ¸íÈ®ÇÑ ºÎ¹®À¸·Î ºÐ·ùÇÕ´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ °¢ ºÎ¹®ÀÇ ¼º°ú¿Í ÀáÀç·ÂÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

°æÀï ȯ°æ : ½ÃÀå Á¡À¯À², Á¦Ç° Æ÷Æ®Æú¸®¿À, Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê, À繫 ½ÇÀû µî ÁÖ¿ä ½ÃÀå Ç÷¹À̾ ´ëÇÑ Á¾ÇÕÀûÀÎ Æò°¡. ÁÖ¿ä ±â¾÷µéÀÌ Ã¤ÅÃÇϰí ÀÖ´Â °æÀï ¿ªÇÐ ¹× ÁÖ¿ä Àü·«¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

½ÃÀå ¿¹Ãø : °ú°Å µ¥ÀÌÅÍ¿Í ÇöÀç ½ÃÀå »óȲÀ» ¹ÙÅÁÀ¸·Î ÀÏÁ¤ ±â°£ µ¿¾È ½ÃÀå ±Ô¸ð¿Í ¼ºÀå Ãß¼¼¸¦ ¿¹ÃøÇÕ´Ï´Ù. ¿©±â¿¡´Â Á¤·®Àû ºÐ¼®°ú ÇâÈÄ ½ÃÀå ±ËÀûÀ» º¸¿©ÁÖ´Â ±×·¡ÇÁ Ç¥½Ã°¡ Æ÷ÇԵ˴ϴÙ.

Áö¿ª ºÐ¼® : Áö¿ªº° ½ÃÀå ¼º°ú¸¦ Æò°¡Çϰí ÁÖ¿ä ½ÃÀå ¹× Áö¿ª µ¿ÇâÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. Áö¿ª ½ÃÀå ¿ªÇÐ ¹× ºñÁî´Ï½º ±âȸ¸¦ ÀÌÇØÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

»õ·Î¿î Æ®·»µå¿Í ±âȸ : ÇöÀç ½ÃÀå µ¿Çâ°ú »õ·Î¿î ½ÃÀå µ¿Çâ, ±â¼ú Çõ½Å, ÀáÀçÀû ÅõÀÚ ´ë»ó ºÐ¾ß¸¦ ÆÄ¾ÇÇÕ´Ï´Ù. ÇâÈÄ ½ÃÀå °³Ã´ ¹× ¼ºÀå Àü¸Á¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ÇöȲ

Á¦3Àå Á¤¸ÆÇ÷Àü»öÀüÁõ Ä¡·á »ê¾÷ ºÐ¼®

  • ¼Ò°³ - ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ¾÷°è µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀå ¸Å·Â ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀÚÀç ºÐ¼®
    • ¿øÀÚÀç ¸®½ºÆ®
    • ¿øÀÚÀç Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿øÀÚÀç °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
  • ¸¶ÄÉÆÃ Ã¤³Î
    • Á÷Á¢ ¸¶ÄÉÆÃ
    • °£Á¢ ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå Á¤¸ÆÇ÷Àü»öÀüÁõ Ä¡·á ¼¼°è ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • Á¦Ç°º° °³¿ä
  • Á¦Ç°º° °ú°Å ¹× ¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • ºñºÐÇÒÇü °ø±â¾Ð ¾ÐÃà ÆßÇÁ
  • ±¸¹è ¾ø´Â ºÐÇÒÇü °ø±â¾Ð ¾ÐÃà ÆßÇÁ
  • ±³Á¤ ±¸¹è ÀÖ´Â ºÐÇÒÇü °ø±â¾Ð ¾ÐÃà ÆßÇÁ
  • »óºÎ °ø±â¾Ð ¾ÐÃà ½½¸®ºê
  • ÇϺΠ°ø±â¾Ð ¾ÐÃà ½½¸®ºê
  • ¿µ±¸ ÇÏ´ëÁ¤¸Æ ÇÊÅÍ
  • ȸ¼ö °¡´ÉÇÑ ÇÏ´ëÁ¤¸Æ ÇÊÅÍ
  • »öÀü dz¼± Ä«Å×ÅÍ
  • °æÇÇÀû Ç÷ÀüÁ¦°Å ±â±â
  • Ä«Å×ÅÍ Á÷Á¢ Ç÷Àü¿ëÇØ(CDT) ±â±â

Á¦6Àå Á¤¸ÆÇ÷Àü»öÀüÁõ Ä¡·á ¼¼°è ½ÃÀå ºÐ¼® : Áúȯº°

  • Áúȯº° °³¿ä
  • Áúȯº° °ú°Å ¹× ¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • ½ÉºÎÁ¤¸ÆÇ÷ÀüÁõ
  • Æó»öÀüÁõ

Á¦7Àå Á¤¸ÆÇ÷Àü»öÀüÁõ Ä¡·á ¼¼°è ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • ÃÖÁ¾»ç¿ëÀÚº° °³¿ä
  • ÃÖÁ¾»ç¿ëÀÚº° °ú°Å ¹× ¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • º´¿ø
  • Ä«Å×ÅÍ °Ë»ç½Ç
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ

Á¦8Àå Á¤¸ÆÇ÷Àü»öÀüÁõ Ä¡·á ¼¼°è ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼Ò°³
  • ºÏ¹ÌÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • À¯·´ : ºÎ¹®º°
    • À¯·´ : ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º°
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå Á¤¸ÆÇ÷Àü»öÀüÁõ Ä¡·á ±â¾÷ °æÀï ±¸µµ

  • Á¤¸ÆÇ÷Àü»öÀüÁõ Ä¡·á ½ÃÀå °æÀï
  • Á¦ÈÞ/Çù·Â/ÇÕÀÇ
  • ÀμöÇÕº´
  • ½ÅÁ¦Ç° ¹ß¸Å
  • ±âŸ °³¹ß

Á¦10Àå ±â¾÷ °³¿ä

  • »óÀ§ ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • Stryker Corporation
  • Argon Medical Devices
  • Cardinal Health(Medtronic)
  • Cook Medical
  • Boston Scientific Corporation
  • Koninklijke Philips N.V.
  • Arjo
  • DJO Global
ksm 25.04.08

Global Venous Thromboembolism Treatment Market size is anticipated to grow from USD 1.81 Billion in 2024 to USD 2.7 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 4.53% during the forecast period of 2026 to 2033.

The venous thromboembolism (VTE) treatment market is experiencing significant growth, driven by the increasing prevalence of VTE conditions, including deep vein thrombosis (DVT) and pulmonary embolism (PE). As awareness of the risks associated with VTE rises, healthcare providers are prioritizing effective prevention and treatment strategies. The market is witnessing a surge in demand for anticoagulant therapies, including direct oral anticoagulants (DOACs) and traditional anticoagulants, as clinicians seek to improve patient outcomes and reduce the incidence of VTE-related complications.

Innovations in treatment options and delivery methods are shaping the future of the VTE treatment market. The development of novel anticoagulant agents with improved safety profiles and dosing regimens is enhancing the therapeutic landscape for VTE management. Additionally, advancements in patient monitoring technologies, such as wearable devices and telehealth solutions, are enabling healthcare providers to track patient adherence and outcomes more effectively. As research continues to explore the underlying mechanisms of VTE, the market is likely to witness the introduction of targeted therapies that address specific risk factors and patient populations.

Moreover, the VTE treatment market will benefit from increased investment in clinical research and development, as pharmaceutical companies and academic institutions recognize the unmet needs in this area. Collaborative efforts between healthcare providers, researchers, and industry stakeholders will be essential in advancing clinical trials and ensuring the successful implementation of innovative therapies. As the landscape evolves, regulatory bodies are expected to streamline approval processes for new treatments, facilitating faster access to effective solutions for patients with VTE. The focus will increasingly shift towards integrating VTE management into comprehensive healthcare strategies, emphasizing the importance of prevention, early detection, and personalized treatment plans in improving patient outcomes.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Product

  • Non-Segmented Pneumatic Compression Pumps
  • Segmented Pneumatic Compression Pumps without Gradient
  • Segmented Pneumatic Compression Pumps with Calibrated Gradient
  • Upper Pneumatic Compression Sleeves
  • Lower Pneumatic Compression Sleeves
  • Permanent Inferior Vena Cava Filters
  • Retrievable Inferior Vena Cava Filters
  • Embolectomy Balloon Catheters
  • Percutaneous Thrombectomy Devices
  • Catheter-Directed Thrombolysis (CDT) Devices

By Disease Indication

  • Deep Venous Thrombosis
  • Pulmonary Embolism

By End User

  • Hospitals
  • Catheterisation Laboratories
  • Ambulatory Surgical Centres
  • COMPANIES PROFILED
  • Stryker Corporation
  • Argon Medical Devices
  • Cardinal Health (Medtronic)
  • Cook Medical
  • Boston Scientific Corporation
  • Koninklijke Philips N.V.
  • Arjo
  • DJO Global
  • The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. VENOUS THROMBOEMBOLISM TREATMENT INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porters Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Product
    • 3.7.2 Market Attractiveness Analysis By Disease Indication
    • 3.7.3 Market Attractiveness Analysis By End User
    • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL VENOUS THROMBOEMBOLISM TREATMENT MARKET ANALYSIS BY PRODUCT

  • 5.1. Overview By Product
  • 5.2. Historical and Forecast Data Analysis By Product
  • 5.3. Non-Segmented Pneumatic Compression Pumps Historic and Forecast Sales By Regions
  • 5.4. Segmented Pneumatic Compression Pumps without Gradient Historic and Forecast Sales By Regions
  • 5.5. Segmented Pneumatic Compression Pumps with Calibrated Gradient Historic and Forecast Sales By Regions
  • 5.6. Upper Pneumatic Compression Sleeves Historic and Forecast Sales By Regions
  • 5.7. Lower Pneumatic Compression Sleeves Historic and Forecast Sales By Regions
  • 5.8. Permanent Inferior Vena Cava Filters Historic and Forecast Sales By Regions
  • 5.9. Retrievable Inferior Vena Cava Filters Historic and Forecast Sales By Regions
  • 5.10. Embolectomy Balloon Catheters Historic and Forecast Sales By Regions
  • 5.11. Percutaneous Thrombectomy Devices Historic and Forecast Sales By Regions
  • 5.12. Catheter-Directed Thrombolysis (CDT) Devices Historic and Forecast Sales By Regions

6. GLOBAL VENOUS THROMBOEMBOLISM TREATMENT MARKET ANALYSIS BY DISEASE INDICATION

  • 6.1. Overview By Disease Indication
  • 6.2. Historical and Forecast Data Analysis By Disease Indication
  • 6.3. Deep Venous Thrombosis Historic and Forecast Sales By Regions
  • 6.4. Pulmonary Embolism Historic and Forecast Sales By Regions

7. GLOBAL VENOUS THROMBOEMBOLISM TREATMENT MARKET ANALYSIS BY END USER

  • 7.1. Overview By End User
  • 7.2. Historical and Forecast Data Analysis By End User
  • 7.3. Hospitals Historic and Forecast Sales By Regions
  • 7.4. Catheterisation Laboratories Historic and Forecast Sales By Regions
  • 7.5. Ambulatory Surgical Centres Historic and Forecast Sales By Regions

8. GLOBAL VENOUS THROMBOEMBOLISM TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2 North America By Segment Sales Analysis
    • 8.3.3 North America By Country Sales Analysis
    • 8.3.4 United States Sales Analysis
    • 8.3.5 Canada Sales Analysis
    • 8.3.6 Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2 Europe By Segment Sales Analysis
    • 8.4.3 Europe By Country Sales Analysis
    • 8.4.4 United Kingdom Sales Analysis
    • 8.4.5 France Sales Analysis
    • 8.4.6 Germany Sales Analysis
    • 8.4.7 Italy Sales Analysis
    • 8.4.8 Russia Sales Analysis
    • 8.4.9 Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2 Asia Pacific By Segment Sales Analysis
    • 8.5.3 Asia Pacific By Country Sales Analysis
    • 8.5.4 China Sales Analysis
    • 8.5.5 India Sales Analysis
    • 8.5.6 Japan Sales Analysis
    • 8.5.7 South Korea Sales Analysis
    • 8.5.8 Australia Sales Analysis
    • 8.5.9 South East Asia Sales Analysis
    • 8.5.10 Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2 Latin America By Segment Sales Analysis
    • 8.6.3 Latin America By Country Sales Analysis
    • 8.6.4 Brazil Sales Analysis
    • 8.6.5 Argentina Sales Analysis
    • 8.6.6 Peru Sales Analysis
    • 8.6.7 Chile Sales Analysis
    • 8.6.8 Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2 Middle East & Africa By Segment Sales Analysis
    • 8.7.3 Middle East & Africa By Country Sales Analysis
    • 8.7.4 Saudi Arabia Sales Analysis
    • 8.7.5 UAE Sales Analysis
    • 8.7.6 Israel Sales Analysis
    • 8.7.7 South Africa Sales Analysis
    • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE VENOUS THROMBOEMBOLISM TREATMENT COMPANIES

  • 9.1. Venous Thromboembolism Treatment Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10. COMPANY PROFILES OF VENOUS THROMBOEMBOLISM TREATMENT INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Stryker Corporation
    • 10.3.1 Company Overview
    • 10.3.2 Company Revenue
    • 10.3.3 Products
    • 10.3.4 Recent Developments
  • 10.4. Argon Medical Devices
    • 10.4.1 Company Overview
    • 10.4.2 Company Revenue
    • 10.4.3 Products
    • 10.4.4 Recent Developments
  • 10.5. Cardinal Health (Medtronic)
    • 10.5.1 Company Overview
    • 10.5.2 Company Revenue
    • 10.5.3 Products
    • 10.5.4 Recent Developments
  • 10.6. Cook Medical
    • 10.6.1 Company Overview
    • 10.6.2 Company Revenue
    • 10.6.3 Products
    • 10.6.4 Recent Developments
  • 10.7. Boston Scientific Corporation
    • 10.7.1 Company Overview
    • 10.7.2 Company Revenue
    • 10.7.3 Products
    • 10.7.4 Recent Developments
  • 10.8. Koninklijke Philips N.V.
    • 10.8.1 Company Overview
    • 10.8.2 Company Revenue
    • 10.8.3 Products
    • 10.8.4 Recent Developments
  • 10.9. Arjo
    • 10.9.1 Company Overview
    • 10.9.2 Company Revenue
    • 10.9.3 Products
    • 10.9.4 Recent Developments
  • 10.10. DJO Global
    • 10.10.1 Company Overview
    • 10.10.2 Company Revenue
    • 10.10.3 Products
    • 10.10.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦